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ABSTRACT  
 
 
 
LIESL PAGE-SHIPP: TB/HIV integration at primary care level: a quantitative assessment at 
three clinics in Johannesburg, South Africa 
(Under the direction of Prof Annelies van Rie and Ms Lori Evarts) 
 
 
 
In 2004 the WHO released the Interim Policy on Collaborative TB/HIV activity. 
Implementation in South Africa and globally remains sub-optimal. We quantified TB/HIV 
integration at three primary health care clinics in Johannesburg, South Africa by 
retrospectively reviewing routinely collected data. Of 1104 people receiving HIV testing, 306 
(28%) were HIV positive, only 57% had a CD4 count, few received TB screening or 
Isoniazid preventive therapy. Among HIV positive clinic encounters, 921 (15%) had 
documented TB symptoms, but only 10% were microbiologically assessed, and few 
asymptomatic patients were offered IPT. Infection control was poorly documented and 
implemented. Among 208 TB patients, 155 (75%) had documented HIV status, 90% were 
HIV positive and 88% had a documented CD4 count. Provision of CPT and ART was poorly 
documented. The lack of standardized recording tools and incomplete documentation 
impeded assessment at facility level, and limits the accuracy of data compiled at district 
level.  
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Abstract  
 
Objective 
In 2004 the WHO released the Interim Policy on Collaborative TB/HIV activities. For People 
living with HIV (PLWH), activities include intensified case finding, isoniazid preventive therapy (IPT) 
and infection control. For TB patients, activities include HIV counseling and testing (HCT), prevention 
messages, and cotrimoxazole preventive therapy (CPT); care and support, and antiretroviral 
treatment (ART) for those with HIV-associated TB. Implementation of collaborative activities in South 
Africa and globally remains sub-optimal. We aimed to quantify TB/HIV integration at three primary 
health care clinics in Johannesburg, South Africa. 
 
Methods 
Routinely collected TB and HIV data from the HCT register, TB suspect register, TB 
treatment register, clinic file and HIV electronic database collected over a period of three months was 
reviewed.  
 
Results  
Of 1104 people receiving HCT, 306 (28%) were HIV positive, only 57% of these had a CD4 
count, few were screened for TB or offered IPT. Among all clinic encounters with PLWH, 921 (15%) 
had documented TB symptoms, but only 10% were assessed by smear microscopy, and few 
asymptomatic PLWH were offered IPT. Infection control was poorly documented and implemented. 
Among 208 TB patients, 155 (75%) had documented HIV status, of which 90% were HIV positive and 
88% had a documented CD4 count. Provision of CPT and ART was poorly documented. 
 
Conclusion 
Coverage of most TB/HIV collaborative activities was below global plan targets. The lack of 
standardized recording tools and incomplete documentation impeded assessment at facility level, and 
limits the accuracy of data compiled at district level.  
 
3-6 Key words Integration, PLWH, diagnosis, guidelines, WHO 
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INTRODUCTION  
HIV-associated tuberculosis (TB) continues to pose an important global public health threat. 
In 2010, 1.1 million (13%) of the 8.8 million new TB cases globally were among people living with HIV 
(PLWH) and HIV accounted for 25% of the 1.4 million TB deaths. South Africa ranked third in the 
number of incident TB cases in 2010 with an estimated 61% of TB patients living with HIV. Despite 
important efforts to curb the TB epidemic, South Africa was the only high-burden country where the 
TB burden continued to rise in 2010 (WHO, 2011).  
To address the HIV-associated TB epidemic, the World Health Organization (WHO) 
published the Interim Policy on Collaborative TB/HIV activities in 2004 (Stop TB Department and 
Department of HIV / AIDS, 2004). To decrease the burden of TB in PLWH, the guidelines recommend 
intensified TB case-finding (ICF), isoniazid preventive therapy (IPT), and infection control in health 
care and congregate settings. In 2008, these activities were packaged as the “3Is” (WHO 3Is). To 
decrease the burden of HIV in TB patients, the guidelines promote HIV counselling and testing (HCT) 
and HIV prevention methods for all TB patients, and cotrimoxazole preventive therapy (CPT) and 
HIV/AIDS care and support including antiretroviral treatment (ART) for those coinfected.  
Despite an increasing body of evidence (Harries, Zachariah, & Lawn, 2009); Hoffmann et 
al.,2010) on the effectiveness and feasibility of collaborative TB/HIV activities and recent 
improvements in TB/HIV integration, implementation remains below targets (WHO, 2011a). In 2010, 
58% of PLWH were screened for symptoms of TB, and 12% of those eligible started IPT. Globally 
34% TB patients knew their HIV status, of which 23% were HIV positive. Almost 80% of TB patients 
living with HIV received CPT, and 46% were on ART (WHO,2011). Only 52% of all countries 
implemented infection control training; data on TB infection among health care workers was not yet 
available (WHO, 2011). 
We reviewed routine TB and HIV data to quantify TB/HIV integration at three primary health 
care clinics in Johannesburg, South Africa. 
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METHODS 
Study setting and population  
Three primary health care clinics in the Johannesburg metropolitan area were purposefully 
selected to represent different geographical catchment areas and non-governmental and Department 
of Health clinics. All clinics provide TB diagnosis and treatment services, HCT, pre-ART care, and 
continuation of ART for stable patients; two sites also initiated ART. TB and HIV services were 
performed vertically in different areas of the clinic by different staff who self-identified as either “HIV” 
or “TB” staff. 
Voluntary counselling and testing was performed in those who requested this service, and 
provider-initiated HCT was offered to pregnant women and clients with symptoms of AIDS, including 
TB and sexually transmitted diseases. CPT was indicated in PLWH with CD4 count < 200 cells/mm
3
, 
symptomatic HIV disease and all TB patients (South African National Department of Health, 2008). 
PLWH eligible for ART were those with CD4 count < 200 cells/mm
3 
and/or WHO stage 4 disease 
(South African National Department of Health, 2004). PLWH were eligible for IPT if they were 
asymptomatic for TB and had a positive tuberculin skin test or were a TB contact (South African 
National Department of Health, 2008). Clinic clients with cough for more than 2 weeks were 
considered TB suspects, independent of HIV status. The first line diagnostic for TB was smear 
microscopy; and guidelines indicated that smear negative TB suspects should be further assessed by 
culture and chest X-ray(South African National Department of Health, 2008).Sputum analysis was 
performed at the centralized National Health Laboratory Services. Clients were referred to the closest 
hospital for chest X-ray.  
All clinic clients who presented to one of the three selected clinics between 19 August and 19 
October 2009 and received TB and/or HIV services were included in the analysis. Eligible clinic 
clients were identified by review of relevant data sources, including the paper South African National 
Department of Health (NDOH) HCT register, TB Case identification and follow up register and TB 
treatment register and an electronic HIV database (TherapyEdge Inc., Littleton, Massachusetts, USA) 
(Table 1). Records of all eligible individuals were reviewed 2 months after their clinic visit to allow 
sufficient time for activities to be performed and results to be captured. Infection control was 
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assessed using a standardised Risk Assessment Tool developed by the USAID Tuberculosis Project. 
This tool is based on the National TB Infection control guidelines (South African National Department 
of Health, 2007) and includes quantitative and qualitative assessments of administrative and 
environmental controls and personal protective equipment. 
In the analysis, individuals were categorized as “HCT client” if they received HCT during the 
study period, “TB suspect“ if they had a diagnostic sputum investigation recorded, and “TB patient” if 
they were started on TB treatment during the study period. Because the WHO guidelines recommend 
symptom screening at every clinic visit, we included all PLWH encounters, including multiple 
encounters by individual PLWH that occurred during the specified time period. 
Clinic records from clients who newly tested HIV positive were reviewed for documentation of 
TB symptom screening and their names were cross-checked with the “TB Detection and Follow up 
Sputum Register” to assess if a sputum specimen was obtained. Data on PLWH was extracted from 
the TherapyEdge database. For every encounter registered, the record of symptoms and signs was 
reviewed. For every PLWH with any cough, night sweats, weight loss, axillary nodules and fever 
recorded, the “TB Detection and Follow up Sputum Register” was cross-checked to assess if a 
sputum specimen was obtained. Clinic files of clients entered into the TB Case Identification and 
Follow up Register and/or the TB register were reviewed for HIV testing, CD4 count, CPT status and 
ART status.  
All data from standardised NDOH registers and TherapyEdge were entered for analysis in 
eMuM (Geomed, Stellenbosch, South Africa), a TB/HIV electronic clinic and patient management 
program. Descriptive statistics were used to characterize the study population. SAS (version 9.2, 
SAS, Inc., Cary, NC, USA) was used for analysis.  
Study approval was granted by the Human Research Ethics Committee, University of 
Witwatersrand; the Institutional Review Board, University of North Carolina; City of Johannesburg 
Health Department; and facility managers.  
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RESULTS  
 
Activities to reduce the burden of TB among PLWH 
 
HCT clients were young (median age 27 years) and predominantly female (75%). Of the 
1104 clients tested, 306 (28%) were HIV-positive. Only 57% of HIV positive patients had a CD4 count 
result recorded, with a median count of 336 cells/mm
3 
(IQR: 152-502). The proportion of clients newly 
diagnosed with HIV who were screened for TB symptoms could not be determined, as this activity 
was not systematically recorded.  Based on review of the TB case identification register, only 2 of the 
306 (0.6%) HIV-positive HCT clients were assessed by smear microscopy at the time of their HCT 
visit.  
There were 6157 clinic encounters for 4079 individual PLWH. The majority (79%) were for 
patients on ART (Table 2). The proportion of individuals with any recorded TB symptom of any 
duration was slightly higher for pre-ART than ART visits (17% vs. 14%, p=0.04). In both populations, 
cough was the most frequently recorded symptom (85% and 70%). Of the 921 clinic encounters with 
TB symptoms documented, only 91 (10%) resulted in sputum being collected, with similar proportions 
of pre-ART and ART suspects being investigated (12% and 9%, respectively, p=0.20). Among the 91 
TB suspects investigated, 8 smear positive pulmonary TB cases and 9 smear negative culture 
positive TB cases were diagnosed. A culture result was missing or contaminated in 27% (22/83) of 
smear negative TB suspects. 
The clinics did not collect information on IPT in an IPT register, pre-ART register or in the 
electronic HIV system, making an accurate estimate of the number of people on IPT difficult. 
According to the clinic directors, a small number of PLWH received IPT in one clinic; the other two 
clinics did not provide IPT. 
An infection control plan existed in two sites, and posters on cough hygiene were displayed in 
all three facilities. Staff training was ad-hoc, management reported that an effort was made to 
educate staff on TB and encourage them to know their HIV status and seek appropriate care. There 
was no triage system or fast-tracking of coughing patients. Environmental controls were inconsistently 
used, 30% of windows remained closed. One site had UV lights in the TB clinic area. Personal 
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protection for staff interacting with patients in the form of N95 respirator or surgical masks was 
available at one clinic but use was not enforced. TB disease in health care workers was not 
documented.  
 
 
Activities to reduce the burden of HIV among TB patients 
 
Among the 602 TB suspects, 173 (29%) were known HIV positive before their suspect visit 
but only half had documentation of receiving HIV care (Table 3). Among the 429 TB suspects with 
unknown HIV status, half 217, (51%) had a record of HCT offer. Of these, 51% (110) were HIV 
positive, 20% (43) were HIV negative, and 29% (64) refused HIV testing. Overall, the proportion of TB 
suspects for whom the HIV status was recorded was 54%, with 73% (95% CI: 0.83, 0.90) HIV 
infected.  
A CD4 cell count was documented in 78% (222/283) of HIV-positive TB suspects, The 
proportion of suspects staged by CD4 cell count and the median CD4 count did not differ significantly 
between those with known status at time of presentation and those tested on the day of the TB 
suspect visit [76% vs. 82%, respectively, p=0.27; and 190 (IQR: 90, 351) vs. 183 (IQR: 61, 289) 
cells/mm
3
, respectively].  
Among the 602 TB suspects, 143 (24%) were diagnosed with active TB: 80 (56%) with smear 
positive TB, 25 (17%) with smear negative, culture positive TB, 27 (19%) based on clinical and/or 
radiological criteria, and 11 (8%) with extrapulmonary TB. Among the 494 smear negative TB 
suspects, a culture was requested in 345 (70%). The culture was positive for Mycobacterium 
tuberculosis in 5%, negative in 48%, and missing in 17%. Only 81% (65/80) of TB suspects positive 
on smear microscopy and 26% (7/27) of smear-negative suspects with a positive culture-positive 
initiated TB treatment.  
During the three-month study period, 208 patients received TB treatment; the majority (81%) 
for pulmonary TB. The proportion of TB patients aware of their HIV status increased from 39% before 
the TB diagnosis to 66% at time of TB treatment initiation to 75% during TB treatment (Figure 1). 
Among the 155 TB patients with known HIV status, 90% were HIV positive. Almost all (88%) HIV 
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positive TB patients had a documented CD4 cell count. Median CD4 cell count was 131 cells /mm
3 
(IQR: 60-235), of which the vast majority (107/123, 87%) had a CD4 count below 350 cells/mm
3
. 
There was no documentation of HIV prevention counseling for HIV positive or HIV negative patients, 
but condoms were freely available at all there clinics. According to the staff, most HIV-positive TB 
patients received CPT but the proportion on CPT could not be quantified as this was not documented 
in the TB register and not consistently recorded in the patient files. Information on ART status was not 
consistently recorded, and patients receiving TB treatment at a clinic not accredited for ART initiation 
may have initiated ART in another facility, making accurate reporting of the proportion receiving ART 
impossible.  
 
 
DISCUSSION  
In this quantitative evaluation of collaborative TB/HIV activities at three primary care clinics, we 
confirmed the magnitude of the TB/HIV epidemic and observed strengths and gaps in the fight 
against TB/HIV at primary care level, but were challenged by the weaknesses in the routine data 
required to report on WHO core indicators developed to monitor TB/HIV activities.  
 While 1104 people received HCT during the three-month period, this activity occurred in 
relative isolation, as people newly diagnosed with HIV were not routinely screened for TB symptoms, 
were not offered IPT, and only 57% had a CD4 count recorded. Howard et al. demonstrated that a 
simple TB symptom screen can be successfully integrated into primary health care.(Howard & El-
Sadr, 2010) Among those with a recorded CD4 count, the median CD4 count was 336 cells/mm
3
, 
higher than the median CD4 count of 111 cells/mm
3
 recorded in four large ART cohorts in sub-
Saharan Africa (May et al., 2010). Strengthening pre-ART programmes could thus provide an 
excellent opportunity to improve TB/HIV prevention efforts.  
In contrast to the paper-based recording of HCT, clinic visits for PLWH were recorded 
electronically. Clinical symptoms were not collected as part of a formalised TB screening assessment 
and health care workers rarely acted upon the information, with only 10% of those symptomatic 
assessed by microscopy and few asymptomatic PLWH initiating IPT. The WHO recommends that the 
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TB screening outcome is recorded on the pre-ART or ART register as “no signs”, “suspect”, “on 
treatment” or “not assessed” (Stop TB Department and Department of HIV/AIDS, 2009). Even if 
recorded appropriately, the indicator “percentage of HIV-positive patients screened for TB in HIV care 
or treatment settings” does not reveal whether those identified as suspects are investigated for TB. 
Addition of an indicator “Proportion of symptomatic PLWH assessed for TB” may be useful as this 
indicator will bridge the monitoring gap between TB symptom screening and TB treatment initiation. 
Despite the clear benefits (Akolo, Adetifa, Shepperd, & Volmink, 2010) implementation of IPT has 
been very slow due to the complicated logistics of tuberculin skin testing (Getahun et al., 2010), 
difficulty in excluding TB, and concern of inducing INH resistance (Ait-Khaled et al., 2009). IPT was 
not offered at all in two and infrequently at one clinic.  
While some steps were taken towards infection control, there was much room for 
improvement. The use of a standardised risk assessment tool on a quarterly basis will facilitate 
monitoring of improvements in infection control. Globally, there is no data on the proportion of health-
care facilities providing services for PLWH that have TB infection control practices (indicator B.3.1) or 
the proportion of health care workers who developed TB (indicator B.3.2) (Stop TB Department and 
Department of HIV/AIDS, 2009).  
Similar to global trends, the coverage of activities to reduce the burden of HIV among people 
with TB was higher than the coverage of the 3I’s. A high proportion (75%) of TB patients knew their 
HIV status, and 90% were HIV positive. The majority (88%) had a CD4 count documented but ART 
and CPT coverage could not be established as this information was erratically recorded. We 
observed a high (73%) prevalence of HIV among the 54% of TB suspects with documented HIV 
status. High HIV prevalence among TB suspects has also been reported in other settings (Odhiambo 
et al., 2008; Munthali, Mwaungulu, Munthali, Bowie, & Crampin, 2006)
 
and supports the expansion of 
HCT recommendations to include TB suspects. Monitoring this activity would however require the 
revision of the TB Case identification and follow up register. The finding that 17% of culture results 
were missing points not only to a waste of precious resources but also to quality of TB services. The 
introduction of more sensitive TB diagnostic tools with the potential for use at point of care such as 
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Xpert MTB/RIF(Boehme et al., 2011), and LAM assay (Lawn, Kerkhoff & Vogt, 2011) could improve 
this situation. 
While many have discussed the challenges of TB/HIV integration (Harries, Zachariah & 
Lawn, 2009; Howard & El-Sadr, 2010 ; Dong et al., 2007;
 
Perumal, Padayatchi, & Stiefvater, 2009)
 
little is known about  coverage of the different components at facility level. Most data on TB/HIV 
integration is aggregated at country level, and accurate reporting is complicated by the existence of 
two vertical programmes (Gunneberg, Reid, Williams, Floyd, & Nunn, 2008.) The lack of standard 
documentation of most activities, and the need to cross check multiple paper-based registers, 
resulted in a significantly more challenging and time consuming assessment than anticipated, 
occupying three full time data staff for 6-months to collect data on 3 months of activities in three 
clinics. Two other quantitative assessments have been published. In 2000-2002, Coetzee et al. 
observed many missed opportunities for TB and HIV prevention, diagnosis and management at 
primary care clinics in Khayelitsha, South Africa (Coetzee, Hilderbrand, Goemaere, Matthys, & 
Boelaert, 2004). In 2006, Scott et al. audited TB/HIV integration at sixteen clinics in Cape Town, 
South Africa, using a rapid (2 hour per clinic) audit tool and found poor capacity and weaknesses in 
quality and continuity of care (Scott, Chopra, Azevedo, Caldwell,  Naidoo  & Smuts, 2010). 
 
Despite the strengths of our comprehensive review of data on a large number of clinic clients, 
the study suffered from important limitations. First, in order to assess routine care, data collection was 
retrospective; consequently activities that were performed but not recorded could not be assessed. 
Second, clients may have received some care at other clinics but due to the high number of clinics 
(n=90) in the City of Johannesburg, we were unable to verify this. Third, data was only reviewed on 
adult clinic clients; an assessment of TB/HIV activities in children would have been complementary. 
Finally, South Africa underwent significant policy changes regarding collaborative TB/HIV in 2010. 
ART eligibility changed to a CD4 count < 350 cells/ mm
3
 for TB patients and pregnant women, and all 
MDR-TB patients regardless of CD4 count. The revised IPT guidelines removed the need for TST 
and included patients with previous TB and those on ART. When contacted in February 2012, two 
clinic managers reported an increase in IPT uptake but could not provide an exact number of clients 
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initiated on IPT in 2010. IPT was not yet implemented in the third clinic. These observations highlight 
the slow implementation of guidelines and the continued lack of standardized documentation of IPT.  
 
In conclusion, despite the existence of effective interventions, clear policies and guidelines, 
the TB/HIV epidemic continues to rage. It is encouraging that most TB/HIV activities were 
implemented at the primary care clinics, but unfortunately at coverage levels well below the Global 
Plan targets (Table 4)(WHO, 2011). This highlights the vast number of opportunities to improve HIV 
care and TB control as we move towards meaningful TB/HIV integration. The poor quality of routine 
data was of concern, especially given that primary care clinics are expected to compile data from 
these sources to report to district and national level for aggregation, analysis, dissemination and 
management of the TB and HIV programs. Collection of TB/HIV collaborative data can be 
complicated by privacy concerns (Loveday & Zweigenthal, 2011), the need to share data between 
two vertical programmes, and the lack of investment in monitoring and evaluation tools ( Gunneberg, , 
Reid, Williams, Floyd & Nunn, 2008). Accurate monitoring of TB/HIV activities at all levels (facility, 
district, national, global) requires rationalization and standardization (Loveday & Zweigenthal, 2011)
-
(Harries AD, Zachariah R, Corbett EL, 2010), with appropriate treatment cards, registers, cohort 
reporting forms, and supportive supervision.(Stop TB Department and Department of HIV/AIDS, 2009 
;
 
Harries et al.,2010). Implementation of integrated TB/HIV electronic data collection and clinic 
management tools, have the potential to galvanize TB/HIV integration at primary care level. We need 
to ensure every action is properly recorded and every loop is closed from diagnosis to treatment of 
HIV and TB, resulting in fully integrated TB/HIV patient care. 
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Table 1: Definition of study participants, data sources and activities reviewed at 3 primary care clinics 
in Johannesburg, South Africa 
 Definition Source TB and HIV activities 
performed 
# Reviewed 
during study  
HCT clients Clinic clients with 
record of HIV test 
HCT register 
Medical file 
Intensified TB 
screening 
Staging by CD4 count 
 
1104 
PLWH 
encounters 
Clinic visits by 
PLWH 
Electronic HIV 
database 
TB case 
identification 
register 
Intensified TB 
screening 
Referral for TB 
investigation if 
symptomatic 
 
6157 
TB 
suspects 
Clinic client with 
record of diagnostic 
sputum investigation 
TB case 
identification 
register 
HCT register 
Medical file 
Diagnostics 
assessment of TB 
suspect 
HCT 
CPT and ART if eligible 
 
602 
TB patients 
starting TB 
treatment 
Clinic client with TB 
start date during the 
study period 
TB treatment 
register 
TB clinic file 
HCT 
CPT 
Staging by CD4 count  
ART if eligible 
208 
 
HCT HIV counselling and testing 
PLWH People Living with HIV 
CPT Cotrimoxazole preventive therapy 
ART Antiretroviral Treatment 
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Table 2: Intensified TB case finding among during 6157 clinic encounters among 4079 individual 
PLWH at 3 primary care clinics in Johannesburg, South Africa 
 
  
All Pre-ART ART P value 
 n (%) n (%) n (%)  
Total 6157 
(100%) 
1274 
(21%) 
4883 
(79%) 
 
       
   Any TB symptom recorded* 921 (15%) 214 (17%) 707 (14%) 0.04 
       Cough 678 (74%) 181 (85%) 497 (70%)  
       Weight loss 138 (15%) 38 (18%) 100 (14%)  
       Night sweats 169 (18%) 27 (13%) 142 (20%)  
       Lymphadenopathy 79 (9%) 14 (7%) 65 (9%)  
       Fever 58 (6%) 14 (7%) 44 (6%)  
        
   If symptomatic, investigated for TB 91 (10%) 26 (12%) 65 (9%) 0.20 
      Smear-positive 8 (9%) 2 (8%) 6 (9%)  
      Smear-negative, culture-negative 52 (57%) 17 (65%) 35 (54%)  
      Smear-negative, culture-positive 9 (10%) 1 (4%) 8 (12%)  
      Smear-negative, culture missing/   
          contaminated 
22 (24%) 6 (23%) 16 (25%)  
*Patients may have reported more than one symptom 
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Table 3: HIV activities recorded among 602 TB Suspects at 3 primary care clinics in Johannesburg, 
South Africa 
 n (%) 
HIV counselling and testing   
Known HIV positive before TB suspect visit 173 (29%) 
     Referred from pre-ART care 26 (15%) 
     Referred from ART clinic 65 (38%) 
     No documentation of HIV care  80 (46%) 
HCT at time of TB suspect visit (if unknown HIV status)  
     Record of HIV counselling and/or testing  217 (51%)  
          HIV positive  110 (51%) 
          HIV negative 43 (20%) 
          HIV testing offered but refused 64 (29%) 
     No record of HIV counselling or testing 212 (49%) 
TB suspects with documented HIV status at end of TB suspect 
visit 326 (54%) 
HIV prevalence rate among TB suspects with recorded HIV 
status (95% CI)  73% (0.83, 0.90) 
Staging by CD4 count   
     Recorded CD4 count result  
          Known HIV positive before TB suspect visit 132 (76%) 
          Newly diagnosed HIV infection at time of TB suspect visit  90 (82%) 
     Median CD4 count in cells/mm
3
 (IQR)  
          Known HIV positive before TB suspect visit 190 (90, 351) 
          Newly diagnosed HIV infection at time of TB suspect visit  183 (61, 289) 
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Table 4: Coverage of TB/HIV activities at 3 primary care clinics in Johannesburg, South Africa 
compared to 2010 estimates for South Africa and The Global Plan to Stop TB targets 
Indicator(Stop TB Department and 
Department of HIV/AIDS, 2009) 
 
Global Plan 
Target  
2011- 
2015(WHO, 
n.d.) 
South Africa 
(WHO, 2011a) 
3 primary care clinics in 
Johannesburg 
Percentage of HIV-positive patients who were 
screened for TB in HIV care and treatment 
settings (indicator B.1.1)  
100% 758 837  Not recorded at HCT  
 100% of PLWH in care 
screened for TB symptoms 
 10% of TB suspects 
assessed by smear 
microscopy 
Percentage of new HIV-positive patients 
starting IPT (indicator B.2.1) 
 
100% 124 059 (12%)  0% at 2 clinics 
 Small proportion at 1 clinic 
Proportion of health care facilities providing 
services for people living with HIV that have 
infection control practices that include TB 
control (indicator B.3.1) 
Target not 
set but 
100% 
implied 
NR None of the clinics satisfied the 
requirements for indicator B.3.1. 
Proportion of health-care workers, employed 
in facilities providing care for people living with 
HIV, who developed TB (indicator B.3.2) 
Equal to 
background 
rate 
NR Not recorded 
Proportion of TB patients with known HIV 
status (indicator C.1.1) 
 
100% 54% 
 
75% 
Proportion of all registered TB patients who 
had documented HIV status who are HIV 
positive (indicator C.1.2.1) 
NA 60% 90% 
Availability of free condoms at TB services 
(indicator C.2.1) 
100% NR 100% 
Proportion of HIV-positive TB patients who 
receive CPT (indicator C.3.1) 
100% 74% 
 
High according to HCW but 
poorly documented 
Proportion of HIV-positive TB patients enrolled 
in HIV care services during TB treatment 
(indicator C.4.1) 
100% NR Poorly documented 
Proportion of HIV-positive registered TB 
patients given ART during TB treatment 
(indicator C.5.1) 
100% 54% Poorly documented 
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Fig 1: HIV counseling and testing among 208 TB patients registered at three primary care clinics in 
Johannesburg, South Africa 
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Addendum # 1:  Introduction 
 
Overview of Specific TB/HIV integration activities  
The WHO Interim Policy on Collaborative TB/HIV activities describes TB/HIV integration 
in terms of decreasing the burden of TB in People Living with HIV (PLWH) and decreasing 
the burden of HIV in TB patients (Stop TB Department and Department of HIV / AIDS, 
2004). The WHO annual report details the provision of integrated TB and HIV activities at a 
global and country level to measure the progress of TB/HIV integration (WHO, 2011). 
 
Decreasing the burden of TB in People Living with HIV 
The WHO described the “3Is” of decreasing TB burden in PLWH as Intensified case 
finding (ICF), Isoniazid Preventive Therapy (IPT) and TB infection control in health care 
facilities and congregate settings.  
Intensified Case Finding refers to actively screening for signs of TB in areas where 
HIV patients congregate. It is recognised that early identification of TB and prompt initiation 
of treatment increases the chances of survival, improves quality of life and reduces 
transmission of tuberculosis in the community (Stop TB Department and Department of HIV 
/ AIDS, 2004). 
The TB symptom screen used for ICF was not previously standardised and different 
symptoms and their duration were used; ranging from only screening for “cough” to 
screening for over eight TB symptoms. Getahun et al performed an individual participant 
data meta-analysis of 12 Observational Studies to develop a standardised TB screening tool  
(Getahun et al., 2011).The findings of this meta-analysis were that absence of all of current 
cough, fever, night sweats, and weight loss can identify a subset of people living with HIV 
who have a very low probability of having TB disease. Thus a simplified screening rule using 
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any one of these symptoms is now recommended to identify PLWH in resource-constrained 
settings who require further diagnostic assessment for TB (Getahun et al., 2011). 
This standardised screen will assist in simplifying the process for health-care 
workers (HCWs) and, if implemented consistently and documented accurately, will enable 
more accurate data collection and comparison.  
Despite the relative simplicity and low cost of TB symptom screening, screening was 
only provided for 27% PLWH globally in 2007 (WHO, 2009). This increased significantly to 3 
million (58%) PLWH receiving a TB symptom screen in 2010 (WHO, 2011). The increase 
was especially noted in South Africa where 758 837 PLWH received a TB symptom screen 
in 2010 (WHO, 2011). 
Not only is TB symptom screening key to detecting PLWH who require further 
investigation to exclude TB; but absence of these 4 symptoms is the first step in assessing 
eligibility for Isoniazid Preventive Therapy (Stop TB Department and Department of 
HIV/AIDS, 2011).  IPT is the provision of a single daily dose (5mg/kg/day, max 300mg/day) 
of Isoniazid (INH); one of the four drugs used to treat TB, for 6-9 months. The efficacy of IPT 
in reducing active TB was confirmed as early as 2004 in a Cochrane review of 11 trials 
which included 8 130 randomised participants; this benefit was found to be more significant 
in TST (Tuberculin Skin Test) positive individuals (Volmink & Woldehanna, 2004). A review 
was repeated in 2010, confirming these results (Akolo et al., 2010). 
 Despite clear international and local guidelines; IPT implementation has been very 
slow, in 2007 less than 0.1% eligible patients initiated IPT globally and only 1.5% in South 
Africa (WHO, 2009). Encouraging results are starting to emerge however as global 
implementation has started to increase; 178 144 (12%) of eligible patients started on IPT in 
2010 (WHO, 2011). In South Africa, this improvement was also marked with 124 059 PLWH 
initiating IPT in 2010, representing a five-fold increase in IPT provision since 2009 (WHO, 
2011). 
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In an effort to understand why the implementation of provision of a single, relatively non-
toxic drug for a limited period remains poor, a number of research studies have been 
undertaken to explore barriers to IPT implementation. Barriers identified include the 
complicated logistics of tuberculin skin testing, implementation requires well trained staff, 
and interpretation of the result requires thorough experience and repeated visits by the 
patient (Getahun et al., 2010).  
Although studies have consistently shown reduced efficacy of IPT in tuberculin skin 
test negative individuals (Akolo et al., 2010 ; Samandari et al., 2011) the requirement for 
TST is a barrier to implementation. In the THRio study, one third of patients developed TB 
before the test could be performed (Golub et al., 2010). Local and international guidelines 
thus no longer require a TST as a component of the eligibility criteria for IPT initiation (Stop 
TB Department and Department of HIV/AIDS, 2011 ;  South African National Department of 
Health, 2010). 
Other barriers to IPT implementation include HCW lack of knowledge and 
experience, concern regarding the accurate exclusion of TB (Lester et al., 2010), fears of 
inducing INH resistance (van Halsema et al., 2010) and confusion regarding IPT provision 
with ART (Lester et al., 2010). 
Although trials to assess the efficacy of IPT once patients are on ART have been 
retrospective (Golub et al., 2009; Charalambous et al., 2010), the evidence provided has 
been sufficient for policies to endorse the provision of IPT for patients stabilised on ART. 
This is also consistent with the finding that even in those with viral load suppression on ART, 
TB incidence remains higher than in the general population (Lawn et al., 2011). Although 
there is evidence that prolonged IPT (36 Months) may be superior to 6 months of IPT 
(Samandari et al., 2011) the South African guidelines recommend 6 months; probably a 
realistic goal given the current low coverage of even 6 months of preventive treatment. Task 
shifting can be used to scale up this intervention as it has been shown that IPT can be 
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delivered by nurses using clinical criteria for adverse event monitoring (Grant, Mngadi, van 
Halsema, Luttig & Fielding 2010). 
Many of the cited barriers to IPT are being overcome and there is a growing body of 
evidence to show that IPT does not cause subsequent resistance to INH (Samandari et 
al.,2011; van Halsema et al., 2010). However, a new barrier may be emerging as there is 
growing evidence of PLWH having asymptomatic, culture positive TB (Oni et al., 2011 ; 
Bassett et al.,2010;  Lawn et al., 2011) this may require a revision of criteria for excluding 
TB as many of these patients also tested negative on Xpert MTB/RIF and/or had a normal 
chest-Xray (Oni et al., 2011 ; Bassett et al.,2010 ; Lawn et al., 2011). 
 The third I in TB prevention is TB infection control. The WHO released the 
“Guidelines for the prevention of TB in healthcare facilities in resource limited settings” as 
early as 1999 (WHO, 1999); these guidelines were revised in 2009 (WHO, 2009) but have 
had little impact on practice (WHO, 2011). Data from 2010 show that among the 149 low 
and middle-income countries from which data on infection control were requested, 34 (23%) 
had conducted a national assessment of infection control for TB, and 45 (30%) had a 
national plan for infection control. Training related to infection control was implemented in 78 
(52%) of these countries in 2010 and 79 had a focal point for infection control in at least one 
tertiary hospital (WHO 2011). 
To provide a proxy measurement to assess TB infection control, the WHO developed 
the indicator of “TB notification rate ratio of health-care workers over the general population” 
to monitor infection control, but data is not available globally or for South Africa (WHO, 
2011). WHO is currently leading the development of guidance material regarding how to 
establish surveillance of TB among health-care workers (WHO 2011). 
In South Africa, nosocomial TB transmission was highlighted in the Tugela Ferry 
outbreak in South Africa (Gandhi et al.,2006) with high death rates in what was later to be 
defined as extensively drug-resistant TB (XDR-TB) co-infected patients. South Africa 
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released the National TB Infection Control Guidelines in 2007 (South African National 
Department of Health, 2007) based on those of the WHO (WHO, 2009) which clearly outline 
administrative, environmental and personal protection controls. However, implementation of 
these guidelines remains poor. 
 
 
Decreasing the burden of HIV in TB patients 
To decrease the burden of HIV in TB patients, the WHO guidelines promote HIV 
counselling and testing (HCT) and HIV prevention methods for all TB patients, and 
cotrimoxazole preventive therapy (CPT) and HIV/AIDS care and support including 
antiretroviral treatment (ART) for those who are co infected with TB and HIV (Stop TB 
Department and Department of HIV / AIDS, 2004). 
The WHO reports great progress in scaling up HIV testing. Globally 1 million TB 
patients (16%) knew their HIV status in 2007, 15% were HIV positive. Testing increased to 
34% globally in 2010; of which 23% were HIV positive. This increase was also seen in South 
Africa where 39% of TB patients knew their HIV status in 2009 (73% HIV positive) (WHO 
2009) and 54% of TB patients knew their HIV status (60% HIV positive) in 2010 (WHO, 
2011).  
The HIV prevention methods outlined in the 2004 guideline include promoting safer and 
more responsible sexual behaviour and practices, delayed onset of sexual activity, reduced 
number of sexual partners, systematic use of condoms (male and female) and diagnosis 
and treatment of other sexually transmitted infections (South African National Department of 
Health, 2004). Reduction of parenteral HIV transmission and vertical transmission to infants 
is also emphasised. No data on HIV prevention in the context of TB care is reported by the 
WHO (WHO 2011). 
Cotrimoxazole Preventive Therapy (CPT) is known to be effective in reducing mortality 
in PLWH (Wiktor et al., 1999 ; Nunn et al., 2008) and concerns regarding toxicity and 
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resistance have been addressed (Harries et al., 2009). The WHO recommendation for 
resource-limited settings recognises the benefit of CPT in reducing disease from malaria, 
bacterial infection and diarrhoea and recommends CPT for PLWH with CD4 <350 cells/mm3 
(Sesay et al., 2006) . Recent data from South Africa, a setting with minimal malaria and high 
rates of co-trimoxazole resistant bacteria, demonstrated a 36% reduction in mortality with 
CPT when used with ART (Hoffmann et al., 2010).  
Despite the known benefits of CPT, coverage is not optimal. In 2007, 0.2 million (72%) of 
TB patients received CPT, a small proportion of the 1.4 million estimated PLWH (WHO 
2009). In South Africa data was comparable with 5080 (67%) co-infected patients receiving 
CPT. In 2010 these numbers increased to almost 80% globally and 74% in South Africa 
(WHO, 2011b). 
The fourth intervention described for decreasing the burden of HIV in TB patients is to 
ensure HIV/AIDS care and support. This includes clinical management, prophylaxis, early 
diagnosis, rational treatment and follow-up care for opportunistic infections. Importantly, 
PLWH who complete TB treatment should be provided with a continuum of care and support 
for HIV/AIDS that should be facilitated by a client referral system. Although no specific 
indictors for this fourth intervention are available; the issue of appropriate referral is pertinent 
to this review; rigorous patient level data collection and sharing between the TB and HIV 
programmes is essential to fulfil this requirement. 
The fifth and final intervention to decrease the burden of HIV in TB patients is initiation of 
Antiretroviral treatment, recognising that ART can substantially improve outcomes in TB 
patients (Harries et al., 2009). Despite this, ART coverage has been low. In 2007, only 0.1 
million (34%) received ART globally; 2456 (34%) on ART in South Africa (WHO, 2009). This 
increased significantly in 2010 where almost 80% of eligible patients were on ART and in 
South Africa, 54% of TB patients were receiving ART (WHO, 2011). 
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The latest WHO guidelines recommend ART for all TB patients, regardless of CD4 cell 
count (WHO, 2010). In South Africa, ART is recommended for TB patients with CD4<350 
cells/mm3, to be initiated within 2-8 weeks of TB treatment initiation (South African National 
Department of Health, 2010). Two randomized controlled trials have shown that AIDS-free 
survival is higher with early ART versus delayed ART for patients on TB treatment but this is 
only significant for patients with CD4 <50 cells/mm3   (Abdool Karim et al., 2011; Havlir et al., 
2011). The cumulative lifetime risk of TB in HIV-infected individuals is a function of time 
spent at various CD4-defined levels of risk, both before and during ART (Lawn et al., 2011). 
Once again early diagnosis of HIV and transition into optimal care is essential to maximize 
the potential of ART to influence the TB epidemic. 
In addition to exploring the individual elements of TB/HIV integration as described 
above; a number of studies have been undertaken in various settings to explore the 
challenges of TB/HIV integration.  
 
Overview of TB/HIV integration  
 
TB/HIV integration in South Africa 
The general challenges of TB/HIV integration in South Africa have been described by a 
number of authors as summarised below.  
The most recent paper by Loveday & Zweigenthal (Loveday & Zweigenthal, 2011) sets 
out to identify key obstacles and propose solutions to TB/HIV integration in a health systems 
research case study. The authors used peer-reviewed and grey literature and their own 
experience to identify key obstacles to integration. They reviewed legislation, policies and 
guidelines to determine whether these facilitate or undermine attempts at integration. 
Limitations of the paper include that the process of reviewing the literature is not 
described or evident in the paper and the incorporation of the author’s experience and 
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opinion may bias the findings. However, the points raised were useful in outlining some of 
the broader issues which may hinder TB/HIV integration efforts. Examples include the 
history of political denial around HIV in South Africa which gave rise to the first HIV 
treatment programmes being provided by Non-governmental organizations (NGOs), in a 
parallel system. This parallel system was entrenched by subsequent ring-fenced HIV 
funding once ART was introduced into the public sector. In addition, staff were encouraged 
to continue providing either HIV or TB care. This is particularly evident among the 
Community Health Workers (CHWs) with different cadres providing TB care (”DOTs 
supporters”) and HIV care (“Home-based carers”) who are remunerated differently. 
The authors also outline the conflicting principles which underlie the two programmes; 
ART adherence emphasises patient empowerment whereas the DOTs TB strategy 
promotes paternalism and policing. This is one of only two papers published on the 
challenges of TB/HIV integration, the other being by Harries et al (Harries et al., 2009), 
which highlights the problem of monitoring and evaluation. The principle challenges raised 
are that too much data is being collected, on multiple paper-based cohort data systems with 
two sets of patient’s notes, often stored in different parts of the clinic.  
The solutions of policy change and health system reform proposed in this paper are 
valid, although they may be optimistic. However, the recommendation that all cadres of 
CHWs be combined and trained to provide both TB and HIV care have come to fruition in 
the new Department of Health Primary Health Care Reengineering Plan (South African 
National Department of Health, 2011).  
Perumal et al (Perumal et al., 2009) published a debate which identified similar “high 
level” problems such as parallel, mutually disconnected systems. As a “debate”, once again, 
the authors used their experience to identify problems and their opinion was based on their 
experience; making it similar to that of Loveday & Zweigenthal (Loveday & Zweigenthal, 
2011). However, this paper did refer to some validated methods to improve specific 
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interventions such as Provider Initiated HIV testing (PIT) in TB services, point of care CD4 
testing, ART and IPT. Key missed opportunities identified were counselling and testing, 
surveillance for both TB and HIV at every opportunity, adherence support, infection control 
and positive prevention. 
The paper could have been even stronger if all the available scientific evidence for the 
abovementioned approaches was incorporated to provide a more compelling argument for 
their implementation.  
In 2007, Dong  et al (Dong et al., 2007) discussed the challenges of TB and ART 
delivery, once again within two separate and parallel systems. However, this paper 
specifically focussed on ART and TB treatment adherence support, using the experience of 
the integration of TB in Education and Care for HIV/AIDS (iTEACH) program in KwaZulu 
Natal, the province in South Africa with the highest HIV prevalence.  
The programme is well described and the lessons learned and recommendations for 
ongoing HIV and TB adherence support were based on programme experience. 
Recommendations included the need for effective TB/HIV reference tools and training for 
care providers, individualised adherence counselling and take home materials in the 
patient’s local language, the need for a multi-disciplinary approach and incorporation of 
traditional healers and community support to improve adherence. 
The paper only referenced one similar programme in Kenya; the recommendations 
would have been stronger if other supporting literature was cited. 
Notably lacking in the above-mentioned three papers is the lack of data at clinic 
level. Scott et al (Scott et al., 2010) recognised the challenges of translating policies into 
action and set out to determine how middle managers could be empowered to monitor the 
implementation of effective integrated TB/HIV services at the primary health care level. A 
participatory assessment tool was collaboratively designed with managers. This tool 
28 
 
measured implementation of over 50 indicators, including access, availability and capacity, 
quality, continuity and integration of HIV, TB and STI care. 
The assessment was performed using 635 clinic records at 16 clinics over a two day 
period. Weaknesses in training, quality and continuity of patient care were identified. The 
impact of the assessment results was that managers compiled action plans to address 
weaknesses at their facilities. Findings were well described and the study included relevant 
peer-reviewed literature which assisted in comparisons and strengthened recommendations. 
Although this study, conducted in 2006, represented a useful first step in assessing TB/HIV 
integration at facility level, it was a rapid assessment of only 12% of facilities in the urban 
Cape Town metropole. Only facilities which indicated that they would be open to an 
evaluation process were considered for the assessment; introducing selection bias. 
Although the paper gave a data-driven overview of some key indicators at clinic level, it did 
not present data at the individual patient level; thus the efficacy of TB/HIV integration on 
individuals could not be assessed. 
The only published paper found in the literature review which looked at primary 
health care facility level patient data in South Africa was published by Coetzee et al in 2004 
(Coetzee et al., 2004) using 2001-2002 health information system and clinical data. This 
study was done prior to the release of international or national guidelines on TB/HIV 
integration with the view to assessing whether TB/HIV integration would be beneficial. It was 
conducted in the context of an entrenched national TB programme and a donor-funded HIV 
programme which was in the pilot phase as the SA DOH had not yet initiated ART roll-out in 
the public sector. Although the findings of the study may now appear self-evident, the 
authors showed forward thinking in using the available literature on effective combined 
TB/HIV interventions to assess how to provide more effective patient care. The paper is a 
good example of use of patient level, facility data to give a comprehensive picture of the 
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challenges of TB/HIV integration and the potential benefits to individual patients of improved 
TB/HIV integration. 
One paper was found which directly addressed the issue of TB and HIV data 
collection in South Africa. In 2007, Heunis et al (Heunis et al., 2011) reviewed the accuracy 
of routinely collected data and interviewed nurses to obtain their views on the information 
systems in the Free State, one of the nine provinces of South Africa. Data from 20 facilities 
across the province which represented a cross-section of facilities by urban/rural mix and 
clinic size was reviewed.  
Over 2800 data entries were assessed and an inconsistency rate of 21% was found 
between facility data and that recorded at provincial level. Despite this, the nurse managers 
reported using the data for decision-making. On the one hand this is reassuring in that 
managers recognized the need for data-driven decision-making; on the other, the 
inaccuracy of the data which would guide decisions is clearly a concern. The primary 
recommendation of the interviewed nurses was for an integrated TB/HIV system.  
Although this was a small study, limited to one province, it was a credible attempt to 
quantify the extent of data inaccuracy and the need for a comprehensive review of data 
collection and collation methods both for TB and HIV to inform management decisions. 
 
TB/HIV integration in Sub-Saharan Africa 
Moving further afield, three papers have been published in the last four years which 
describe the overall challenges of TB/HIV integration in Sub-Saharan Africa; including South 
Africa. 
The most recent paper by Howard and El-Sadr (Howard & El-Sadr, 2010) provides an 
overview of the feasibility of TB/HIV integration activities, focussing on the author’s 
experience of supporting programmes which implement ICF, IPT, Infection control, ART and 
nutrition interventions, and integrated programmes. The exact programmes and their 
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locations were not described which makes it difficult to contextualise and compare the 
findings with those of other studies. The authors make good use of existing literature to 
support their recommendations and some of their findings. For example, the use of a TB 
symptom screen is well-substantiated by data from the programmes they support. However, 
the bulk of the article re-iterates issues around TB/HIV integration which have been 
elucidated in other publications with little new data. 
In 2009, Harries et al (Harries et al., 2009) published a perspective on HIV care for co-
infected TB patients. This is an outstanding article in that it combined proven interventions 
with clinical guidelines to synthesise the body of knowledge at the time. The authors 
recognised the need to focus on implementation of effective interventions in the context of 
clinical and programmatic challenges of combining ART and TB treatment. 
With 70 references, scientists and clinicians alike could use this article as a reference 
point for the “state of the ART” in TB/HIV integration at that time. The article clarified which 
interventions were proven and should be implemented (PICT, CPT, IPT, ART) and which 
questions still required clarity, e.g. optimal timing of ART initiation and optimal ART 
regimens for co-infected patients.  
 In 2007, Friedland et al (Friedland, Harries, & Coetzee, 2007) described experience 
in TB/HIV integration in a site in Malawi and two sites in South Africa, in Kwa-Zulu Natal 
(DOH Clinic) and Khayelitsha (NGO clinic) in the Western Cape. The Khayelitsha site was 
the same site describe by Coetzee et al. (Coetzee et al., 2004). The comparison of these 
geographically and programmatically distinct experiences was helpful in that it outlined 
different strategies which may all be effective. Similar to the article by Howard & El Sadr 
(Howard & El-Sadr, 2010), data was limited but the description of three distinct services, as 
opposed to the generalisations presented by Howard & El Sadr, do help the reader to 
contextualise the findings and may be useful at clinic level. 
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TB/HIV integration internationally 
At an international level, Fenner et al (Fenner et al., 2011) described TB-related 
practises in ART programmes in lower–income countries using a standardised electronic 
questionnaire-based survey conducted in 2008. In addition, risk factors for TB in the first 
year of ART were identified. Fifteen ART programmes in 12 countries in Africa, South 
America and Asia, and members of the ART in Lower Income Countries (ART-LINC) 
collaboration of the International Epidemiological Databases to Evaluate AIDS (IeDEA) were 
included.  
Although the paper set out to describe approaches to TB prevention, only IPT 
provision is described. TB symptom screening as part of ICF and TB infection control are 
not mentioned. The article focusses on the provision of TB diagnostics such as sputum 
microscopy, TB culture and chest x-ray within the ART programmes. Although it justifiably 
might be argued that it was not the intention of the paper to comprehensively cover all 
aspects of TB/HIV integration, focussing on only IPT and diagnostics for TB, does not take 
into account the comprehensive approach advocated by WHO. The discussion on effective 
screening strategies which moves directly to diagnostics does not take into account the 
latest WHO recommendations on ICF (Stop TB Department and Department of HIV/AIDS, 
2011). However, the article does mention the latest challenge in TB ICF; pointing to the 
latest trend towards higher TB incidence according to availability of diagnostics. 
In contrast to all the articles described above which related the challenges of TB/HIV 
integration in lower-income countries, Gadowski et al (Gadkowski et al., 2009) described a 
retrospective cohort of TB/HIV infected cases reported in North Carolina between 1993-
2003. In contrast to most programmes in lower-income countries, comprehensive 
surveillance data was available for 5332 TB cases, 553 (10%) of which had known HIV 
infection. The data are clearly presented and thoroughly analysed and demonstrates the 
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tremendous benefit of accurately documented routine data to inform improved monitoring 
and evaluation, and improved patient care.  
The findings of the study showed low utilisation of HIV care prior to TB diagnosis 
with low ART initiation in co-infected patients and high mortality as a result; similar to 
findings in lower-income countries (Fenner et al., 2011). Although this finding may initially be 
surprising, the authors make the point that many co-infected patients in North America may 
also fail to access appropriate health care in the public health system; not unlike co-infected 
patients in lower-income countries (Larson, Brennan, Mcnamara, Long, & Rosen, 2010).  
 Having reviewed the available literature in the context of local and international 
guidelines, it became apparent that there is no recent published operational research 
documenting the coverage of the different components of TB/HIV activities in Sub-Saharan 
Africa in primary health care facilities using patient- level data. 
In South Africa, HIV facility level data are generally collected on a paper based 
system which may include standardised registers. The facilities are then asked to collate 
data and present summary reports at sub-district level. This is collated and presented to the 
district and then to the province. In the case of TB data, a parallel process occurs whereby 
the data from the standardised “TB case identification” register is entered electronically at a 
district level and then submitted to the province.  Facilities have varying staffing levels, 
access to sub-district data and results from facility to provincial level are often disparate; 
resulting in frustration both for the facility, the province and finally errors exist at the National 
level.  
Data provided by WHO is aggregated at country level and reflects the challenges 
related to poor reporting and the complexity of sharing data between two vertical 
programmes (Gunneberg et al., 2008).  
Although aggregated data may be useful for assessing trends, it does not give 
patient-level information which makes it impossible to assess the quality of care individual 
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patients are receiving and where interventions should be targeted. In addition, facilities 
seldom receive feedback on their collated data; making data-driven improvement 
impossible. 
We collated routinely collected HIV and TB facility level data to better understand the 
success and challenges of TB/ HIV integration at the primary health care facility level at 
three clinics in urban Johannesburg, South Africa. 
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Addendum #2: Discussion 
 
The results of this quantitative evaluation represent the gravity of the TB/HIV 
epidemic in South Africa, with at least 90% of TB patients living with HIV and median CD4 
count of 131 cells/mm3 (IQR: 60-235) at presentation.  
HIV care for TB patients appeared to be superior to TB screening in HIV patients; 
findings comparable to a similar setting in Cape Town, South Africa (Scott et al., 2010). 
Successes include reasonable rates of HIV testing among TB patients and high rates of 
CD4 testing for known HIV positive TB suspects and patients. Missed opportunities for 
PLWH included poor documentation of TB symptom screening at HCT, low rates of TB 
diagnostic screening for symptomatic PLWH, no IPT implementation and inadequate 
infection control. Further, poor rates of TB treatment initiation and poor documentation of 
CPT and ART were missed opportunities for TB patients.  
 
Decreasing the burden of TB in People Living with HIV 
The 1104 HCT clients were young (median age 27 years) and predominantly female 
(75%), thought to be representative of young women who present to the clinic for 
contraceptive or ante-natal care. Three hundred and six (28%) were HIV-positive, which 
compares with the 30.2% South African Ante-natal prevalence data in 2010 (South Africa 
National Department of Health, 2010) (Table 5).  
Neither HIV positive or negative patients at HCT were routinely offered TB symptom 
screening. Actual symptom screening performed may be vastly underestimated as health-
care workers may only document findings they consider important or on which they plan to 
act. However one would expect a proportion greater than 0.6% of HIV positive HCT clients 
to be assessed by smear microscopy if this were the case.  
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It has been found that standardised documentation of a simple TB symptom screen 
at each patient visit has been shown to be feasible in a similar setting (Howard & El-Sadr, 
2010). Using this symptom screen, 22% of newly enrolled persons with HIV or AIDS were 
symptomatic and 12% received a diagnosis of TB (Howard & El-Sadr, 2010). A TB symptom 
screen for current cough, fever, weight loss or night sweats not only facilitates intensified TB 
case finding, but also guides eligibility for IPT (Getahun et al., 2011 ; Stop TB Department 
and Department of HIV/AIDS, 2011). There was no referral of asymptomatic patients for IPT 
from HCT, representing a missed opportunity.  
Only 57% of patients found to be HIV positive at HCT had a CD4 recorded; the 
median CD4 count was 336 cells/mm3 (Table 5).  This was higher than the median CD4 
count of 111 cells/mm3 recorded in four large ART cohorts in sub-Saharan Africa (May et al., 
2010). Strengthening pre-ART programmes could thus provide an excellent opportunity to 
improve TB/HIV prevention efforts. In addition, recent publications suggest that Point of 
Care CD4 testing at HCT may be a practical approach to increase the number of diagnosed 
patients who initiate HIV care (Faal, Naidoo, Glencross, Venter,& Osih, 2011) ; (Larson et 
al., 2010). Pre-ART programmes thus provide an excellent opportunity for HIV and TB 
prevention efforts and also ensure that patients commence ART as soon as they are 
eligible.  
In contrast to the paper-based recording of HCT, we recorded information on clinic 
visits among people known to be HIV-infected was recorded electronically. Of the 6157 
clinic encounters the majority (79%) were for patients on ART. 
The presence or absence of TB symptoms was part of routine clinical history data, 
recorded for all clinic encounters with PLWH, resulting in all PLWH having a record of TB 
symptoms. However, the symptoms were not collected as part of a TB screening 
assessment but rather as part of the clinical assessment. This may be one reason why 
health care workers rarely acted upon the presence or absence of TB symptoms. 
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The proportion of individuals with any recorded TB symptom of any duration was 
slightly higher for pre-ART than ART visits (17% vs. 14%, p=0.04). In both populations, 
cough was the most frequently recorded symptom (85% and 70%), a finding in keeping with 
the majority of studies (Getahun et al., 2011). 
Of the 921 clinic encounters with TB symptoms documented, only 91 (10%) resulted 
in sputum being collected, with similar proportions of pre-ART and ART suspects being 
investigated (12% and 9%, respectively, p=0.20). This was clearly a missed opportunity, 
considering that 17 (19%) of those investigated were found to have TB. 
IPT was not provided in these clinics. At the time of this study, local guidelines for 
adult IPT recommended that PLWH with no signs and symptoms of TB, no contraindications 
and a positive tuberculin skin test (TST) or a pulmonary TB contact were eligible for IPT. TB 
preventive therapy was not recommended for patients already on ART or for those with TB 
in the past two years (South African National Department of Health, 2008). Taking into 
account the logistical barriers to TST testing, the latest South African IPT guidelines do not 
require a tuberculin skin test and previous TB is no longer a contraindication. South African 
guidelines are unclear regarding IPT and ART; the IPT guidelines make a conditional 
recommendation of IPT for patients already on ART (South African National Department of 
Health, 2010) however the South African ART guidelines do not recommend IPT once on 
ART (South African National Department of Health, 2010). This seems counter to the 
growing evidence that the benefit of IPT and ART are additive (Samandari  et al., 2011 ; 
Golub et al., 2009 ; (Charalambous et al., 2010) and supports the need for revised 
guidelines. 
Implementation of TB infection control was poor, reflecting the situation in South 
Africa with lack of information and training on existing guidelines.  HCW and administrators 
alike are often pre-occupied with environmental controls and personal protective equipment 
rather than on the more practical administrative controls. At the three study sites there was 
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no system for consistent monitoring of infection control and infection control plans, and site 
assessments as advocated by the guidelines (South African National Department of Health, 
2007) are inconsistently implemented. The initiation of systematic documentation and 
reporting of staff members who develop TB needs to be implemented to understand the 
situation in South Africa, and to allow countries to report numbers of staff members with TB 
as required by the WHO (WHO, 2011) to monitor infection control.  
 
Decreasing the burden of HIV in TB patients 
Similar to global trends, the coverage of activities to reduce the burden of HIV 
among people with TB was higher than the coverage of the 3I’s. 
29% of TB suspects knew their HIV status at time of presentation. Suspicion of TB 
prompted HIV testing with 54% of TB suspects knowing their HIV status by the end of the 
diagnostic process, this opportunity was partially used. Of the TB suspects who knew their 
status, 73% were HIV infected. This high prevalence of HIV in TB suspects is similar to 
other settings in South Africa, 73% (Shah et al., 2011); Kenya 62% (Odhiambo et al., 2008) 
and Malawi 56% (Munthali et al., 2006) and supports the expansion of PICT 
recommendations to include TB suspects in addition to TB patients, which is the current 
recommendation.  This will require revision of the current TB Case identification and follow 
up register which does not have a data field for HIV status; many clinics currently add a 
column to record HIV status on the paper register. 
Among the 602 TB suspects, 143 (24%) were diagnosed with active TB: 80 (56%) 
with smear positive TB, 25 (17%) with smear negative, culture positive TB, 27 (19%) based 
on clinical and/or radiological criteria and 11 (8%) with extra pulmonary TB (Table 6). 
A culture was requested in the majority (70%) of smear negative TB suspects but the 
results was missing in 17%, representing not only a missed opportunity but a waste of 
resources. This waste of resources has been documented elsewhere (Stall et al., 2011). 
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The Xpert MTB/RIF PCR diagnostic has been used effectively in low-resource settings to 
simplify patients’ access to early and accurate diagnosis (Boehme et al., 2011) and this may 
result in less waste. 
Not all smear positive (81%) and only 26% of smear negative, culture positive 
patients initiated TB treatment.This high rate of initial default has been found in other 
settings in South Africa (Botha et al., 2008), Pakistan (Rao, Anwer & Saleem, 2009) and 
Malawi (Squire et al., 2005) and has been attributed to poor quality of health services (Botha 
et al., 2008) and a diagnostic process which is not responsive to patient’s needs (Squire et 
al., 2005). Point of care diagnostics and an electronic patient monitoring system with the 
ability to alert clinicians to missing results and results which need to be acted on which 
should facilitate clinical care and follow up. 
75% of TB patients knew their status after TB treatment initiation which is relatively 
high, but many programs have shown that 84% is achievable (Harries et al., 2011) (Table 
7). Diagnosis of TB provides an important entry point for HIV care and is an opportunity that 
should not be missed (De Cock, Mbori-Ngacha & Marum, 2002; Wood, 2007; Perumal et al., 
2009).  Provider initiated HIV testing has been shown to be acceptable by TB suspects and 
TB patients (Odhiambo et al., 2008; Corneli et al., 2008 ; Levin L, Irving K, Dikgang M, 
Punwasi J, Isaacs M, 2006) and staff (Corneli et al., 2008) and is an opportunity that should 
be exploited. In addition PICT at TB diagnosis has been shown to increase patient’s access 
to ART (Lawn et al., 2011).  
The finding that 90% of TB patients are HIV positive highlights the need to test and 
stage all TB patients. Although the majority (88%) had a CD4 count measured, and 87% 
would have been eligible for ART using the CD4 <350 cells/mm3, there was very poor 
documentation of ART in the TB clinic files. The lack of consistent reporting of ART status 
reflects the negative consequences of a vertical system approach and underscores the lack 
of integration between primary care services and ART services, even within one facility.   
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There was no documentation of HIV prevention counselling for either HIV positive or 
HIV negative TB patients although this may have taken place without being documented.  
Cotrimoxazole Preventive Therapy was not consistently documented although HCWs 
reported using CPT. However, lack of documentation is of concern as it is unlikely that 
patients were consistently receiving this proven intervention. 
Despite a concerted effort to retrieve patient information from all available routine 
sources, a significant amount of data on TB/HIV indicators were missing. There is clearly a 
need for improved record keeping, not just for patient-level data but also for integrated 
TB/HIV data. Consideration needs to be given to the implementation of appropriate 
electronic medical records which have been shown to be more complete, and allow for rapid 
feedback to support indicated services and retention of care in similar settings (Fraser et al., 
2005). Integrated electronic medical records will also contribute to National and global data 
collection, analysis and use (Gunneberg et al., 2008). 
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Table 5: HIV and CD4 results among 1104 clients presenting for HIV Counselling and Testing 
registered at three primary care clinics in Johannesburg, South Africa 
 
                                                        (n) % 
 
 
Median age, years 
27 
  
Sex 
 
   Females              830 (75) 
   Males              274 (25) 
  
HIV test results 
 
   Positive              306 (28) 
   Negative              789 (71) 
   Missing/Pending                    9 (1) 
  
CD4 results   
 
   % HIV positive with CD4 results 174 (57) 
   Median CD4 (cells/mm
3
) 336 
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Table 6: TB diagnosis and TB treatment initiation among 602 TB suspects registered at three primary 
care clinics in Johannesburg, South Africa 
 
                                     n (%)                       n (%) 
   
Median age, years 36 
 
   
Sex 
  
   Females              317 (53) 
 
   Males              285 (47) 
 
   
   
TB diagnosis 143 (24) 
TB treatment 
initiated 
     Smear positive 80 (56) 65   (81) 
     Smear negative, culture positive 25 (17) 7   (26) 
     Clinical and radiological criteria 27 (19) 27 (100) 
     Extrapulmonary TB 11   (8) 11  (100) 
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Table 7: HIV counselling and testing status among 208 TB patients registered at three primary care 
clinics in Johannesburg, South Africa 
 
                                     n (%) 
  
Median age, years 36 
  
Sex 
 
   Females              102 (49) 
   Males              106 (51) 
  
Type of TB 
 
     Pulmonary 168 (81) 
     Extrapulmonary TB 38 (18) 
     Missing records 2   (1) 
  
Known HIV status 
 
     Before TB diagnosis 81 (39) 
     At time of TB treatment initiation 147 (66) 
     During TB treatment 155 (75) 
  CD4 results   
 
   % HIV positive with CD4 results 122 (88) 
   Median CD4 (cells/mm
3
) 131 
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